TOPLINE: An earlier diagnosis of psoriatic arthritis (PsA) following symptom onset increases the likelihood of achieving improved clinical outcomes, highlighting the presence of a diagnostic window […]

TOPLINE: Treatment of patients with rheumatoid arthritis (RA) with non-tumor necrosis factor inhibitor (TNFi) biologic disease-modifying antirheumatic drugs (bDMARDs) may not pose an increased risk for […]

The number of clinically active rheumatology providers in the United States grew more than 20% from 2009 to 2019, according to a new analysis. The number […]

TOPLINE: An analysis of two large, geographically independent gout cohorts revealed distinctly unique clinical and genetic features linked with different subtypes of hyperuricemia, indicating discrete pathophysiologic […]

The rheumatologist of the future will see patients who have been assessed and triaged with artificial intelligence utilizing data from remote kiosk-placed ultrasound scanners and physician-directed […]

The Food and Drug Administration’s approval of leflunomide in September 1998 as a treatment for rheumatoid arthritis was sandwiched between the debuts of infliximab (Remicade and […]

Patients diagnosed with rheumatoid arthritis (RA) and co-occurring anxiety or depression are less likely to achieve low disease activity (LDA) and better symptom control after 3 […]

TOPLINE: Tapering glucocorticoids (GCs) does not increase the risk for flare in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE) with a […]

The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug’s manufacturer, announced today. This is the second tocilizumab biosimilar […]